Statement of Principles concerning dengue virus infection (Reasonable Hypothesis) (No. 78 of 2020)

This instrument is a Statement of Principles concerning dengue virus infection (Reasonable Hypothesis) (No. 78 of 2020), made by the Repatriation Medical Authority under subsection 196B(2) of the Veterans' Entitlements Act 1986 (the VEA) (s3). It commences on 30 November 2020 (s2) and repeals the previous Statement of Principles concerning dengue fever No. 13 of 2012 (s4). The instrument applies to claims that fall within the operation of section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) (s5).

Mechanically, the instrument does three things. First, it defines the disease concept it covers, "dengue virus infection", and the meaning of related terms such as "being exposed to dengue virus" and "terminal event" in an accompanying Schedule 1 - Dictionary (s7(2); Schedule 1). Second, it sets the minimum medical and factual criteria that must exist to raise a reasonable hypothesis connecting dengue virus infection, or death from it, with a person's relevant service , namely at least one of two specified factors: (a) exposure to dengue virus within 14 days before clinical onset; or (b) inability to obtain appropriate clinical management for dengue virus infection (s9). Third, it states relationship-to-service rules: any factor relied on must be related to the person's relevant service, and the management-related factor is limited in scope to material contribution or aggravation where infection was suffered or contracted before or during, but did not arise out of, relevant service (s10).

The instrument is expressly limited to its medical-factual role. It declares the Repatriation Medical Authority’s view that sound medical‑scientific evidence exists to link dengue virus infection and death from the infection with relevant service (s8). It also provides that, where a factor in this instrument refers to an injury or disease already covered by another Statement of Principles, the factors in that other Statement govern as in force from time to time (s11).

The instrument revolves around a tightly circumscribed set of medical and causal concepts drawn from clinical definitions and statutory procedure. The primary definition is "dengue virus infection", defined as an illness caused by infection with dengue virus, with a note on typical and complicated clinical manifestations (s7(2)). The instrument explicitly notes that while dengue attracts ICD‑10‑AM codes A90 or A91, the statutory meaning for the instrument is the textual definition in s7(2) rather than the code alone (s7(3)-(4)).

"Being exposed to dengue virus" is a key operational concept in the Schedule 1 - Dictionary. It is defined by a non‑exclusive list of exposure pathways: (a) being bitten by a mosquito infected with dengue virus; (b) being in a country or an area of a country at a time when there is dengue virus transmission; (c) percutaneous or mucocutaneous exposure to blood infected with dengue virus; (d) sexual contact with an infected person; and (e) receiving blood transfusion, blood products, a stem cell transplant or an organ transplant infected with dengue virus (Schedule 1). The instrument therefore treats both vector (mosquito) exposure and several recognised non‑vector routes as qualifying forms of exposure for the purposes of raising a reasonable hypothesis.

The causal test for a reasonable hypothesis is minimal and binary: at least one of the two enumerated factors in s9 must exist. The first factor is temporal plus exposure, requiring exposure within 14 days before clinical onset (s9(1)). The second factor is systemic and access‑related, being inability to obtain appropriate clinical management for dengue virus infection (s9(2)). The instrument does not itself define "clinical onset" or "appropriate clinical management" in detail, but the schedule defines "dengue virus infection" and "terminal event", and s10 further circumscribes the applicability of s9(2).

"Relevant service" is a statutory term defined in the Schedule by reference to types of service under the VEA and MRCA: operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA (Schedule 1). The instrument therefore links medical causation to a particular statutory class of service.

Finally, the instrument allows cross‑reference to other Statements of Principles: if a factor referred to in s9 relates to an injury or disease already covered by another Statement, the other Statement’s factors apply in accordance with its terms (s11). This is a mechanism to avoid overlap or inconsistency between Statements.

The instrument affects veterans and members of the Forces whose claims for entitlement are assessed under the Veterans' Entitlements Act 1986 or the Military Rehabilitation and Compensation Act 2004. More precisely, it applies to a claim to which section 120A of the VEA or section 338 of the MRCA applies (s5). The Schedule defines "relevant service" by reference to categories of service under the VEA and MRCA, explicitly including operational service, peacekeeping service, hazardous service and British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA (Schedule 1).

Who pays: the instrument does not itself create an entitlement to payment. It functions as a medical standard for decision makers who assess entitlement under the VEA and MRCA. Claimants seeking to have dengue virus infection, or death from it, accepted as service‑related must satisfy the required factual and medical criteria that this Statement of Principles sets out (s9, s10). Medical practitioners, medico‑legal advisers and case managers will be affected in their evidence‑gathering and decision‑making tasks because the instrument specifies what will, at minimum, raise a reasonable hypothesis connecting infection or death to relevant service (s9).

Who decides: the Repatriation Medical Authority made the instrument under s196B(2) of the VEA (s3); however, the instrument itself is used by decision makers under the VEA and MRCA when evaluating claims as to whether a reasonable hypothesis is raised. The instrument does not describe the administrative decision process in detail, but it is framed so that presence of a listed factor, linked to relevant service, is the threshold condition for the statutory test.

Who bears evidential burdens: claimants must provide material establishing at least one of the factors in s9 and evidence linking that factor to their defined relevant service, including for death claims where dengue must have contributed to the terminal event (s7(5); s10). Records showing location, dates of travel or service, timing of clinical onset, medical records evidencing treatment or lack of treatment, and death certificates and clinical cause records will be the core documentary material that flows from the instrument’s definitions and tests.

This Statement of Principles establishes neither regulatory duties nor private rights directly; instead it sets legal‑medical criteria that operate as the baseline for raising a reasonable hypothesis under statutory compensation schemes. The instrument’s key operational duty is implicit: decision makers assessing claims under s120A VEA or s338 MRCA must apply the criteria here when determining whether a reasonable hypothesis exists that links dengue virus infection, or death from it, to relevant service (s5, s9, s10). The instrument itself contains no express procedural obligations, time limits or evidentiary rules, beyond the substantive factors that must exist.

Rights for claimants are procedural and evidentiary. If a claimant can establish at least one of the factors in s9 and demonstrate its relation to their relevant service, a reasonable hypothesis has been raised by that showing (s9, s10). For death cases, the instrument extends the disease concept to include deaths from a terminal event or condition that was contributed to by the person’s dengue virus infection (s7(5)), thereby permitting claimants to rely on evidence that dengue infection materially contributed to a listed terminal event such as pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function (Schedule 1).

The instrument also imposes a limiting rule on how the "inability to obtain appropriate clinical management" factor operates. Subsection 10(2) restricts that factor to circumstances of material contribution or aggravation where the person’s dengue virus infection was suffered or contracted before or during, but did not arise out of, the person's relevant service. In practical terms, this reduces the scope of s9(2) to non‑service‑origin infections that were materially worsened by lack of access to appropriate care during service, rather than to infections that arose directly out of service activities (s10(2)).

There is no penalty regime or criminal sanction included in the instrument. It does not itself confer monetary benefits; it is a medical‑causal benchmark used within the statutory framework of the VEA and MRCA (s3, s5). Decision makers remain bound by the broader statutory processes and review rights under the VEA or MRCA, but those processes are not described in this instrument.

The instrument contains no penal provisions, fines, or criminal sanctions. It is a statutory medical standard established by the Repatriation Medical Authority under the authority of subsection 196B(2) of the VEA (s3). Its enforcement role is procedural and evidentiary within the compensation framework: it specifies the medical and factual circumstances that will, as a minimum, raise a reasonable hypothesis linking dengue virus infection or death from it to the person's relevant service (s9). The instrument thus functions as an authoritative determinant of medical causation for administrative decision makers, but it does not itself set out the administrative enforcement mechanisms, remedies, or sanctions; those remain in the governing statutes (VEA and MRCA) and their administrative procedures.

Because the instrument is declaratory of medical criteria rather than normative about penalties, the practical enforcement consequence is that decision makers in claims management will accept a claim as raising a reasonable hypothesis if the claimant adduces evidence satisfying the instrument’s factors and the service link requirements (s9, s10). Conversely, absence of any qualifying factor in s9 is, on its face, a reason for a decision maker not to conclude that a reasonable hypothesis has been raised. The instrument also provides for interplay with other Statements of Principles: if a factor refers to an injury or disease covered by another Statement, the other Statement’s factors govern (s11), which can influence assessment outcomes.

The instrument does not describe internal review, merits review or judicial review processes, nor does it stipulate sanctions for false claims. Any enforcement or corrective action, including adverse findings, claim denial, administrative review, or further investigation, would proceed under the applicable provisions of the VEA and MRCA and the administrative law regime, not under this instrument itself. The instrument’s legal weight derives from its role as the medical standard to be applied by those statutory processes.

This Statement of Principles is made under subsection 196B(2) of the VEA and explicitly applies to claims governed by section 120A of the VEA or section 338 of the MRCA (s3, s5). It therefore operates within, and as part of, the statutory architecture of veterans’ compensation and rehabilitation law. The instrument cross‑references the International Classification of Diseases, Tenth Revision, Australian Modification (ICD‑10‑AM) for coding context, but it expressly states that the statutory meaning of “dengue virus infection” is the textual definition in s7(2), notwithstanding the attachment of ICD‑10‑AM codes A90 and A91 to dengue disease (s7(3)-(4)). The ICD reference is to the Tenth Edition effective 1 July 2017, ISBN noted in the instrument (s7(4)).

The instrument contains a specific mechanism for addressing overlap with other Statements of Principles. Subsection 11 provides that if a factor referred to in s9 applies in relation to a person and that factor refers to an injury or disease covered by another Statement determined under s196B(2) of the VEA, then the factors in that other Statement apply according to its terms as in force from time to time (s11). This delegates resolution of overlapping causation issues to whichever Statement best encapsulates the relevant disease, avoiding duplicated or inconsistent criteria.

By defining "relevant service" in the Schedule with reference to VEA and MRCA service classes, the instrument ties its causation tests to the statutory definitions used throughout veterans’ law (Schedule 1). That creates coherence with entitlement tests and service classifications in the VEA and MRCA, but it also means that the instrument’s operation depends on the legal characterisation of a person’s service under those Acts.

The instrument does not amend or displace other provisions of the VEA or MRCA. It is a specialised medical instrument that decision makers apply when assessing whether a reasonable hypothesis exists. Any interaction that affects outcomes,such as the application of evidentiary rules, review rights, or payment of benefits,occurs through the VEA and MRCA procedures rather than through this instrument itself. The instrument’s repeal of the 2012 Statement of Principles on dengue fever (s4) is an express interaction, replacing that prior instrument as the operative medical standard for the disease.

The instrument is dated 30 October 2020 and commences on 30 November 2020 (s2). It expressly repeals the prior Statement of Principles concerning dengue fever No. 13 of 2012 as published in the Federal Register of Legislation (s4). The text includes no other amendments, transitional provisions or savings clauses, and it does not record prior amendments to this instrument itself.

The statutory authority for the instrument is subsection 196B(2) of the VEA (s3). The instrument therefore sits in a statutory stream of Statements of Principles created under that provision. The Schedule notes definitions such as "MRCA" and "VEA", which are expressions drawn from other statutes; the instrument does not alter those Acts, it uses their terms.

Because the instrument replaces the 2012 Statement, practitioners should be alert to the differences between the current text and the 2012 text when advising on claims that relate to periods before the new commencement date. This instrument does not include a transitional clause addressing whether and how claims that arose prior to commencement are to be treated; the instrument simply states its commencement date and that it repeals the earlier Statement (s2, s4). Any practical transitional treatment will be determined by the administering agency’s practices and the VEA/MRCA frameworks, but such procedures are not set out in this instrument.

No subsequent amendments or replacement instruments are recorded in the text provided. For up‑to‑date advice or action on amendments after this instrument's commencement, one must consult the Federal Register of Legislation or the Repatriation Medical Authority records; the instrument itself contains no further amendment history.

The text provided contains no litigation history. The instrument does not reference any cases, judicial decisions, or reviews that interpret or apply it, nor does it cite any precedents. It contains a medical‑scientific claim by the Repatriation Medical Authority that there is sound medical‑scientific evidence that dengue virus infection and death from dengue virus infection can be related to relevant service (s8), but it does not identify studies, findings, or legal determinations.

Accordingly, there is no case law contained within the instrument to indicate how courts or tribunals have interpreted its factors, the 14‑day exposure window, the meaning of "inability to obtain appropriate clinical management", or the application of s10 restrictions. Practitioners must therefore treat the instrument as an administrative medical standard to be applied under the VEA and MRCA, and look to external jurisprudence, administrative decisions, and the parties’ submissions in particular claims for guidance on contested interpretations. The instrument itself provides no litigation record.

If litigants or advisers require statements of how tribunals have applied this instrument in individual claim adjudications, they will need to search administrative decisions and judicial reviews outside this text. The instrument contains no internal guidance about dispute resolution, merits review, or judicial appeal processes.

The instrument is precise in some respects and silent or minimal in others, producing several practical pitfalls for advisers and claimants:

• Narrow timing rule for vector/non‑vector exposure: s9(1) requires being exposed to dengue virus within 14 days before clinical onset. The instrument does not define "clinical onset". Advisers must therefore consider medical records carefully to align symptom onset dates with claimed exposure episodes. The 14‑day window is the minimum temporal requirement to raise a reasonable hypothesis (s9(1)).

• Broad definition of "being exposed": Schedule 1 lists several exposure pathways including mosquito bite, presence in a country or area with dengue transmission, percutaneous or mucocutaneous blood exposure, sexual contact, and infected blood or organ products. Presence in an area with transmission qualifies as exposure even without a recorded bite (Schedule 1). This can help claims where specific mosquito bite evidence is absent, but it introduces evidentiary complexity because the claimant must prove presence in an area at a time of transmission.

• "Inability to obtain appropriate clinical management" is not defined: s9(2) names inability to obtain appropriate clinical management as an alternate qualifying factor. The instrument does not define what constitutes appropriate management, nor what evidence will satisfy inability to obtain it. Subsection 10(2) limits that factor to cases where the infection was suffered or contracted before or during, but did not arise out of, relevant service, and where inability to obtain management materially contributed to or aggravated the condition (s10(2)). Advisers should note the two‑part constraint: causation and timing.

• Relationship to service requirement: Any factor in s9 must be related to the person’s relevant service (s10(1)). That requires an evidential linkage between exposure or treatment failure and the statutory category of service in the Schedule, such as operational or peacekeeping service. The Schedule’s definitions of relevant service are categorical, not descriptive, so advisers must match service history to those statutory categories.

• Death claims require contribution to terminal event: For a death to be covered, dengue virus infection must have contributed to the terminal event or condition listed as examples in the Schedule (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) (s7(5); Schedule 1). The instrument does not limit the list to those items alone but includes them as examples. Proving contribution to a terminal event will require medical records and cause of death evidence.

For claimants, advisers and decision makers the instrument sets a focused checklist of facts to establish. To raise a reasonable hypothesis under this Statement of Principles, the claimant must, at minimum, establish the existence of at least one of the factors in s9 and the requisite link to relevant service under s10. Practical steps flow from the definitions and restrictions in the instrument.

1. Establish timing and clinical onset. Obtain medical records that record the date of clinical onset of dengue‑compatible symptoms, or laboratory confirmation of dengue, to situate the 14‑day exposure window required by s9(1). Where laboratory tests are available, include them. Because the instrument does not define "clinical onset", contemporaneous clinical notes, emergency department records, or hospital admission notes will be important.

2. Prove exposure under the Schedule. Use the Schedule’s five exposure pathways to identify evidence that matches one or more. For mosquito exposure or presence in an area with transmission, obtain service records, travel itineraries, unit movement logs, public health notices, or contemporaneous reports that place the person in an area known to have dengue virus transmission at the relevant time (Schedule 1). For percutaneous or mucocutaneous exposures, obtain incident reports and medical records. For sexual transmission or transfusion/organ transmission, obtain laboratory and clinical evidence linking the source and timing.

3. If relying on inability to obtain appropriate clinical management (s9(2)), document attempts to obtain care, records of denial or delay, and contemporaneous medical consequences showing material contribution or aggravation. Remember that s10(2) restricts reliance on this factor to infections suffered or contracted before or during, but not arising out of, relevant service, and it requires material contribution or aggravation by the lack of appropriate care.

4. Document relevant service. Compile service records that demonstrate the claimant’s category of relevant service as defined in the Schedule (operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, or warlike/non‑warlike service under the MRCA). Match dates and locations of service to exposure episodes to satisfy the s10(1) link between factor and relevant service.

5. For death claims, obtain cause of death documents, autopsy or coroner reports, and clinical notes showing how dengue infection contributed to the terminal event. The instrument treats death from dengue virus infection as including deaths from terminal events or conditions to which dengue contributed (s7(5)).